
    
      Patients with Rheumatoid Arthritis and started treatment with adalimumab in a normal clinical
      setting according to the label were documented. The follow-up observation period was for 5
      years and focused on safety information and maintenance of efficacy during the normal
      clinical setting. Follow-up with participants was via regular office visits at intervals as
      determined by routine clinical practice or as recommended by national guidelines.
    
  